1. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling
- Author
-
Ke, Lin, Na, Yang, Wu, Luo, Jin-Fu, Qian, Wei-Wei, Zhu, Shi-Ju, Ye, Chen-Xin, Yuan, Di-Yun, Xu, Guang, Liang, Wei-Jian, Huang, and Pei-Ren, Shan
- Subjects
Inflammation ,Pharmacology ,Palmitic Acid ,General Medicine ,Rats ,Mice, Inbred C57BL ,Transcription Factor AP-1 ,Mice ,Glucosides ,Animals ,Myocytes, Cardiac ,Pharmacology (medical) ,Obesity ,Benzhydryl Compounds ,Cardiomyopathies ,Sodium-Glucose Transporter 2 Inhibitors - Abstract
Obesity is an important independent risk factor for cardiovascular diseases, remaining an important health concern worldwide. Evidence shows that saturated fatty acid-induced inflammation in cardiomyocytes contributes to obesity-related cardiomyopathy. Dapagliflozin (Dapa), a selective SGLT2 inhibitor, exerts a favorable preventive activity in heart failure. In this study, we investigated the protective effect of Dapa against cardiomyopathy caused by high fat diet-induced obesity in vitro and in vivo. Cultured rat cardiomyocyte H9c2 cells were pretreated with Dapa (1, 2.5 μM) for 1.5 h, followed by treatment with palmitic acid (PA, 200 μM) for 24 h. We showed that Dapa pretreatment concentration-dependently attenuated PA-induced cell hypertrophy, fibrosis and apoptosis. Transcriptome analysis revealed that inhibition of PA-activated MAPK/AP-1 pathway contributed to the protective effect of Dapa in H9c2 cells, and this was confirmed by anti-p-cJUN fluorescence staining assay. Using surface plasmon resonance analysis we found the direct binding of Dapa with NHE1. Gain and loss of function experiments further demonstrated the role of NHE1 in the protection of Dapa. In vivo experiments were conducted in mice fed a high fat diet for 5 months. The mice were administered Dapa (1 mg·kg
- Published
- 2022
- Full Text
- View/download PDF